Nicholas Galakatos - Net Worth and Insider Trading

Nicholas Galakatos Net Worth

The estimated net worth of Nicholas Galakatos is at least $10 Million dollars as of 2024-11-13. Nicholas Galakatos is the 10% Owner of Rigel Pharmaceuticals Inc and owns about 183,360 shares of Rigel Pharmaceuticals Inc (RIGL) stock worth over $5 Million. Nicholas Galakatos is the Director, 10% Owner of Entasis Therapeutics Holdings Inc and owns about 1,623,405 shares of Entasis Therapeutics Holdings Inc (ETTX) stock worth over $4 Million. Nicholas Galakatos is also the Director, 10% Owner of Astria Therapeutics Inc and owns about 45,875 shares of Astria Therapeutics Inc (ATXS) stock worth over $512,424. Besides these, Nicholas Galakatos also holds IVERIC bio Inc (ISEE) , NS Wind Down Co Inc (NSTGQ) , Affymax Inc (AFFY) . Details can be seen in Nicholas Galakatos's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Nicholas Galakatos has not made any transactions after 2018-09-28 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Nicholas Galakatos

Nicholas Galakatos Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Nicholas Galakatos owns 28 companies in total, including Praxis Precision Medicines Inc (PRAX) , Entasis Therapeutics Holdings Inc (ETTX) , and NS Wind Down Co Inc (NSTGQ) among others .

Click here to see the complete history of Nicholas Galakatos’s form 4 insider trades.

Insider Ownership Summary of Nicholas Galakatos

Ticker	Comapny	Transaction Date	Type of Owner
PRAX	Praxis Precision Medicines Inc	2020-10-15	director
ETTX	Entasis Therapeutics Holdings Inc	2019-06-19	director
NSTGQ	NS Wind Down Co Inc	2018-09-17	director & 10 percent owner
		2018-07-02	10 percent owner
		2017-10-11	10 percent owner
		2011-05-17	10 percent owner
		2015-06-30	director & 10 percent owner
		2016-02-08	10 percent owner
		2016-01-11	director & 10 percent owner
		2015-06-15	10 percent owner
		2013-10-25	10 percent owner
		2014-10-28	10 percent owner
		2014-06-27	director
		2012-08-02	other: Managing dir. of GP
		2012-08-11	10 percent owner
		2012-06-04	10 percent owner
		2011-10-27	10 percent owner
		2011-09-16	10 percent owner
		2010-03-11	director & 10 percent owner
		2010-12-14	other: Former 10% Owner
		2007-08-03	other: See explanation below
		2010-09-30	10 percent owner
		2010-01-27	10 percent owner
		2009-11-05	10 percent owner
		2009-05-28	director & 10 percent owner
		2004-07-02	10 percent owner
		2004-03-10	10 percent owner
		2021-05-06	director

Nicholas Galakatos Latest Holdings Summary

Nicholas Galakatos currently owns a total of 6 stocks. Among these stocks, Nicholas Galakatos owns 183,360 shares of Rigel Pharmaceuticals Inc (RIGL) as of July 2, 2004, with a value of $5 Million and a weighting of 51.28%. Nicholas Galakatos owns 1,623,405 shares of Entasis Therapeutics Holdings Inc (ETTX) as of September 28, 2018, with a value of $4 Million and a weighting of 36.53%. Nicholas Galakatos also owns 45,875 shares of Astria Therapeutics Inc (ATXS) as of June 30, 2015, with a value of $512,424 and a weighting of 5.26%. The other 3 stocks IVERIC bio Inc (ISEE) , NS Wind Down Co Inc (NSTGQ) , Affymax Inc (AFFY) have a combined weighting of 6.93% among all his current holdings.

Latest Holdings of Nicholas Galakatos

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
RIGL	Rigel Pharmaceuticals Inc	2004-07-02	183,360	27.22	4,991,059
ETTX	Entasis Therapeutics Holdings Inc	2018-09-28	1,623,405	2.19	3,555,257
ATXS	Astria Therapeutics Inc	2015-06-30	45,875	11.17	512,424
ISEE	IVERIC bio Inc	2016-01-11	9,629	39.95	384,679
NSTGQ	NS Wind Down Co Inc	2018-09-17	4,036,025	0.07	289,666
AFFY	Affymax Inc	2006-12-14	49,998	0.00	40

Holding Weightings of Nicholas Galakatos

Nicholas Galakatos Form 4 Trading Tracker

According to the SEC Form 4 filings, Nicholas Galakatos has made a total of 0 transactions in Rigel Pharmaceuticals Inc (RIGL) over the past 5 years. The most-recent trade in Rigel Pharmaceuticals Inc is the sale of 165 shares on July 2, 2004, which brought Nicholas Galakatos around $25,325.

According to the SEC Form 4 filings, Nicholas Galakatos has made a total of 0 transactions in Entasis Therapeutics Holdings Inc (ETTX) over the past 5 years. The most-recent trade in Entasis Therapeutics Holdings Inc is the acquisition of 453,395 shares on September 28, 2018, which cost Nicholas Galakatos around $7 Million.

According to the SEC Form 4 filings, Nicholas Galakatos has made a total of 0 transactions in Astria Therapeutics Inc (ATXS) over the past 5 years. The most-recent trade in Astria Therapeutics Inc is the acquisition of 6,278 shares on June 30, 2015, which cost Nicholas Galakatos around $5 Million.

More details on Nicholas Galakatos's insider transactions can be found in the Insider Trading History of Nicholas Galakatos table.

Insider Trading History of Nicholas Galakatos

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Nicholas Galakatos Trading Performance

GuruFocus tracks the stock performance after each of Nicholas Galakatos's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Nicholas Galakatos is -28.87%. GuruFocus also compares Nicholas Galakatos's trading performance to market benchmark return within the same time period. The performance of stocks bought by Nicholas Galakatos within 3 months outperforms 0 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Nicholas Galakatos's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Nicholas Galakatos

Average Return

Average return per transaction

Outperforming Transactions

1 out of 3 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-5.52
Relative Return to S&P 500(%)	-4.96

Nicholas Galakatos Ownership Network

Ownership Network List of Nicholas Galakatos

No Data

Ownership Network Relation of Nicholas Galakatos

Nicholas Galakatos Owned Company Details

What does Praxis Precision Medicines Inc do?

Who are the key executives at Praxis Precision Medicines Inc?

Nicholas Galakatos is the director of Praxis Precision Medicines Inc. Other key executives at Praxis Precision Medicines Inc include Chief Executive Officer Marcio Souza , Chief Financial Officer Timothy Edwin Kelly , and Principal Accounting Officer Lauren Mastrocola .

Praxis Precision Medicines Inc (PRAX) Insider Trades Summary

Over the past 18 months, Nicholas Galakatos made no insider transaction in Praxis Precision Medicines Inc (PRAX). Other recent insider transactions involving Praxis Precision Medicines Inc (PRAX) include a net purchase of 14,500 shares made by Jill Desimone , and a net purchase of 10,000 shares made by Marcio Souza .

In summary, during the past 3 months, insiders sold 0 shares of Praxis Precision Medicines Inc (PRAX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Praxis Precision Medicines Inc (PRAX) were sold and 1,633 shares were bought by its insiders, resulting in a net purchase of 1,633 shares.

Praxis Precision Medicines Inc (PRAX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Praxis Precision Medicines Inc Insider Transactions

No Available Data

What does Entasis Therapeutics Holdings Inc do?

Who are the key executives at Entasis Therapeutics Holdings Inc?

Nicholas Galakatos is the director of Entasis Therapeutics Holdings Inc. Other key executives at Entasis Therapeutics Holdings Inc include 10 percent owner Theravance Inc , VP & Principal Fin & Acct Off Kristie Ann Wagner , and Chief Medical Officer David Altarac .

Entasis Therapeutics Holdings Inc (ETTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Entasis Therapeutics Holdings Inc (ETTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Entasis Therapeutics Holdings Inc (ETTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Entasis Therapeutics Holdings Inc (ETTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Entasis Therapeutics Holdings Inc Insider Transactions

No Available Data

What does NS Wind Down Co Inc do?

Who are the key executives at NS Wind Down Co Inc?

Nicholas Galakatos is the director & 10 percent owner of NS Wind Down Co Inc. Other key executives at NS Wind Down Co Inc include Chief Commercial Officer Jonathan Todd Garland , Chief Financial Officer K Thomas Bailey , and director & President and CEO R Bradley Gray .

NS Wind Down Co Inc (NSTGQ) Insider Trades Summary

Over the past 18 months, Nicholas Galakatos made no insider transaction in NS Wind Down Co Inc (NSTGQ). Other recent insider transactions involving NS Wind Down Co Inc (NSTGQ) include a net purchase of 35,400 shares made by William Young , a net purchase of 30,000 shares made by R Bradley Gray , and a net purchase of 15,000 shares made by K Thomas Bailey .

In summary, during the past 3 months, insiders sold 0 shares of NS Wind Down Co Inc (NSTGQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of NS Wind Down Co Inc (NSTGQ) were sold and 80,400 shares were bought by its insiders, resulting in a net purchase of 80,400 shares.

NS Wind Down Co Inc (NSTGQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

NS Wind Down Co Inc Insider Transactions

No Available Data

What does Forty Seven Inc do?

Who are the key executives at Forty Seven Inc?

Nicholas Galakatos is the 10 percent owner of Forty Seven Inc. Other key executives at Forty Seven Inc include Chief Financial Officer Ann D Rhoads , 10 percent owner Lightspeed General Partner X, L.p. , and 10 percent owner Lightspeed Ultimate General Partner X, Ltd. .

Forty Seven Inc (FTSV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Forty Seven Inc (FTSV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Forty Seven Inc (FTSV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Forty Seven Inc (FTSV)'s detailed insider trading history can be found in Insider Trading Tracker table.

Forty Seven Inc Insider Transactions

No Available Data

What does Venus Concept Inc do?

Who are the key executives at Venus Concept Inc?

Nicholas Galakatos is the 10 percent owner of Venus Concept Inc. Other key executives at Venus Concept Inc include 10 percent owner Michael Willingham Masters , President Global Sales Ross Portaro , and 10 percent owner Masters Special Situations, Llc .

Venus Concept Inc (VERO) Insider Trades Summary

Over the past 18 months, Nicholas Galakatos made no insider transaction in Venus Concept Inc (VERO). Other recent insider transactions involving Venus Concept Inc (VERO) include a net sale of 958,979 shares made by Michael Willingham Masters ,

In summary, during the past 3 months, insiders sold 469,031 shares of Venus Concept Inc (VERO) in total and bought 0 shares, with a net sale of 469,031 shares. During the past 18 months, 958,979 shares of Venus Concept Inc (VERO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 958,979 shares.

Venus Concept Inc (VERO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Venus Concept Inc Insider Transactions

No Available Data

What does Radius Health Inc do?

Who are the key executives at Radius Health Inc?

Nicholas Galakatos is the 10 percent owner of Radius Health Inc. Other key executives at Radius Health Inc include director & CEO and President G. Kelly Martin , Senior Vice President Elizabeth Messersmith , and Vice President & Sales Danielle Holtschlag .

Radius Health Inc (RDUS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Radius Health Inc (RDUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Radius Health Inc (RDUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Radius Health Inc (RDUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Radius Health Inc Insider Transactions

No Available Data

What does Astria Therapeutics Inc do?

Who are the key executives at Astria Therapeutics Inc?

Nicholas Galakatos is the director & 10 percent owner of Astria Therapeutics Inc. Other key executives at Astria Therapeutics Inc include Chief Medical Officer Christopher Morabito , director & 10 percent owner Perceptive Life Sciences Master Fund Ltd , and Chief Business Officer Andrea Matthews .

Astria Therapeutics Inc (ATXS) Insider Trades Summary

Over the past 18 months, Nicholas Galakatos made no insider transaction in Astria Therapeutics Inc (ATXS). Other recent insider transactions involving Astria Therapeutics Inc (ATXS) include a net purchase of 4,295,958 shares made by Perceptive Life Sciences Master Fund Ltd , and a net sale of 20,000 shares made by Christopher Morabito .

In summary, during the past 3 months, insiders sold 0 shares of Astria Therapeutics Inc (ATXS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 20,000 shares of Astria Therapeutics Inc (ATXS) were sold and 4,295,958 shares were bought by its insiders, resulting in a net purchase of 4,275,958 shares.

Astria Therapeutics Inc (ATXS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Astria Therapeutics Inc Insider Transactions

No Available Data

What does TetraLogic Pharmaceuticals Corp do?

Who are the key executives at TetraLogic Pharmaceuticals Corp?

Nicholas Galakatos is the 10 percent owner of TetraLogic Pharmaceuticals Corp. Other key executives at TetraLogic Pharmaceuticals Corp include other: See Remarks Hudson Bay Capital Management Lp , other: See Remarks Lazard Asset Management Llc , and other: See Remarks Nomura Holdings Inc .

TetraLogic Pharmaceuticals Corp (TLOG) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of TetraLogic Pharmaceuticals Corp (TLOG) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of TetraLogic Pharmaceuticals Corp (TLOG) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

TetraLogic Pharmaceuticals Corp (TLOG)'s detailed insider trading history can be found in Insider Trading Tracker table.

TetraLogic Pharmaceuticals Corp Insider Transactions

No Available Data

What does IVERIC bio Inc do?

Who are the key executives at IVERIC bio Inc?

Nicholas Galakatos is the director & 10 percent owner of IVERIC bio Inc. Other key executives at IVERIC bio Inc include SVP & COO Keith Westby , SVP & CFO and Treasurer David Francis Carroll , and Senior Vice President & CCO Christopher Paul Simms .

IVERIC bio Inc (ISEE) Insider Trades Summary

Over the past 18 months, Nicholas Galakatos made no insider transaction in IVERIC bio Inc (ISEE). Other recent insider transactions involving IVERIC bio Inc (ISEE) include a net sale of 40,000 shares made by Keith Westby ,

In summary, during the past 3 months, insiders sold 0 shares of IVERIC bio Inc (ISEE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 40,000 shares of IVERIC bio Inc (ISEE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 40,000 shares.

IVERIC bio Inc (ISEE)'s detailed insider trading history can be found in Insider Trading Tracker table.

IVERIC bio Inc Insider Transactions

No Available Data

What does Oxford Immunotec Global PLC do?

Who are the key executives at Oxford Immunotec Global PLC?

Nicholas Galakatos is the 10 percent owner of Oxford Immunotec Global PLC. Other key executives at Oxford Immunotec Global PLC include director & Chief Executive Officer Peter Wrighton-smith , Chief Financial Officer Mclaughlin Matthew T E , and Chief Operating Officer Stefan C Linn .

Oxford Immunotec Global PLC (OXFD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Oxford Immunotec Global PLC (OXFD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Oxford Immunotec Global PLC (OXFD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Oxford Immunotec Global PLC (OXFD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Oxford Immunotec Global PLC Insider Transactions

No Available Data

What does Aerie Pharmaceuticals Inc do?

Who are the key executives at Aerie Pharmaceuticals Inc?

Nicholas Galakatos is the 10 percent owner of Aerie Pharmaceuticals Inc. Other key executives at Aerie Pharmaceuticals Inc include Chief Financial Officer Peter Frederick Lang , director & Chief Executive Officer Raj Kannan , and Vice President of Finance Jeffrey Calabrese .

Aerie Pharmaceuticals Inc (AERI) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aerie Pharmaceuticals Inc (AERI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aerie Pharmaceuticals Inc (AERI) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aerie Pharmaceuticals Inc (AERI)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aerie Pharmaceuticals Inc Insider Transactions

No Available Data

What does Sientra Inc do?

Who are the key executives at Sientra Inc?

Nicholas Galakatos is the 10 percent owner of Sientra Inc. Other key executives at Sientra Inc include director & President and CEO Ronald Menezes , General Counsel and VP Oliver Christian Bennett , and Chief Financial Officer Andrew C Schmidt .

Sientra Inc (SIENQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sientra Inc (SIENQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sientra Inc (SIENQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sientra Inc (SIENQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sientra Inc Insider Transactions

No Available Data

What does Portola Pharmaceuticals Inc do?

Who are the key executives at Portola Pharmaceuticals Inc?

Nicholas Galakatos is the director of Portola Pharmaceuticals Inc. Other key executives at Portola Pharmaceuticals Inc include EVP & General Counsel John B Moriarty , EVP and CFO Mardi Dier , and EVP & CMO Rajiv Patni .

Portola Pharmaceuticals Inc (PTLA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Portola Pharmaceuticals Inc (PTLA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Portola Pharmaceuticals Inc (PTLA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Portola Pharmaceuticals Inc (PTLA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Portola Pharmaceuticals Inc Insider Transactions

No Available Data

What does Globus Medical Inc do?

Who are the key executives at Globus Medical Inc?

Nicholas Galakatos is the other: Managing dir. of GP of Globus Medical Inc. Other key executives at Globus Medical Inc include Senior VP and CFO Daniel T Scavilla , SVP & General Counsel Kelly Huller , and director & Vice President & Operations David D Davidar .

Globus Medical Inc (GMED) Insider Trades Summary

Over the past 18 months, Nicholas Galakatos made no insider transaction in Globus Medical Inc (GMED). Other recent insider transactions involving Globus Medical Inc (GMED) include a net sale of 95,000 shares made by David D Davidar , a net sale of 20,000 shares made by Kelly Huller , and a net sale of 106,750 shares made by Dan Lemaitre .

In summary, during the past 3 months, insiders sold 162,500 shares of Globus Medical Inc (GMED) in total and bought 0 shares, with a net sale of 162,500 shares. During the past 18 months, 308,340 shares of Globus Medical Inc (GMED) were sold and 0 shares were bought by its insiders, resulting in a net sale of 308,340 shares.

Globus Medical Inc (GMED)'s detailed insider trading history can be found in Insider Trading Tracker table.

Globus Medical Inc Insider Transactions

No Available Data

What does Humanigen Inc do?

Who are the key executives at Humanigen Inc?

Nicholas Galakatos is the 10 percent owner of Humanigen Inc. Other key executives at Humanigen Inc include 10 percent owner Dale Chappell , Chief Medical Officer Adrian Kilcoyne , and Chief Commercial Officer Edward P. Jordan .

Humanigen Inc (HGENQ) Insider Trades Summary

Over the past 18 months, Nicholas Galakatos made no insider transaction in Humanigen Inc (HGENQ). Other recent insider transactions involving Humanigen Inc (HGENQ) include a net sale of 386,350 shares made by Dale Chappell ,

In summary, during the past 3 months, insiders sold 0 shares of Humanigen Inc (HGENQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 386,350 shares of Humanigen Inc (HGENQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 386,350 shares.

Humanigen Inc (HGENQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Humanigen Inc Insider Transactions

No Available Data

What does Achillion Pharmaceuticals Inc do?

Who are the key executives at Achillion Pharmaceuticals Inc?

Nicholas Galakatos is the 10 percent owner of Achillion Pharmaceuticals Inc. Other key executives at Achillion Pharmaceuticals Inc include EVP & Chief Commercial Officer Paul E Firuta , EVP & Chief Medical Officer Steven Zelenkofske , and General Counsel Martha E Manning .

Achillion Pharmaceuticals Inc (ACHN) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Achillion Pharmaceuticals Inc (ACHN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Achillion Pharmaceuticals Inc (ACHN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Achillion Pharmaceuticals Inc (ACHN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Achillion Pharmaceuticals Inc Insider Transactions

No Available Data

What does EPIRUS Biopharmaceuticals Inc do?

Who are the key executives at EPIRUS Biopharmaceuticals Inc?

Nicholas Galakatos is the 10 percent owner of EPIRUS Biopharmaceuticals Inc. Other key executives at EPIRUS Biopharmaceuticals Inc include Chief Business Officer Vincent Aurentz , Chief Financial Officer Thomas A. Shea , and director & Chief Executive Officer Amit Munshi .

EPIRUS Biopharmaceuticals Inc (EPRSQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of EPIRUS Biopharmaceuticals Inc (EPRSQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of EPIRUS Biopharmaceuticals Inc (EPRSQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

EPIRUS Biopharmaceuticals Inc (EPRSQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

EPIRUS Biopharmaceuticals Inc Insider Transactions

No Available Data

What does Zogenix Inc do?

Who are the key executives at Zogenix Inc?

Nicholas Galakatos is the 10 percent owner of Zogenix Inc. Other key executives at Zogenix Inc include EVP & CHIEF COMMERCIAL OFFICER Ashish M Sagrolikar , EVP/Chief Development Officer Gail M Farfel , and director & President and CEO Stephen J Farr .

Zogenix Inc (ZGNX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Zogenix Inc (ZGNX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Zogenix Inc (ZGNX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Zogenix Inc (ZGNX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Zogenix Inc Insider Transactions

No Available Data

What does AVEO Pharmaceuticals Inc do?

Who are the key executives at AVEO Pharmaceuticals Inc?

Nicholas Galakatos is the director & 10 percent owner of AVEO Pharmaceuticals Inc. Other key executives at AVEO Pharmaceuticals Inc include Chief Operating Officer Jebediah Ledell , director & President & CEO Michael P Bailey , and Chief Commercial Officer Michael Ferraresso .

AVEO Pharmaceuticals Inc (AVEO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of AVEO Pharmaceuticals Inc (AVEO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of AVEO Pharmaceuticals Inc (AVEO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

AVEO Pharmaceuticals Inc (AVEO)'s detailed insider trading history can be found in Insider Trading Tracker table.

AVEO Pharmaceuticals Inc Insider Transactions

No Available Data

What does Reshape Lifesciences Inc do?

Who are the key executives at Reshape Lifesciences Inc?

Nicholas Galakatos is the other: Former 10% Owner of Reshape Lifesciences Inc. Other key executives at Reshape Lifesciences Inc include Chief Financial Officer Thomas Stankovich , President and CEO Barton P. Bandy , and director & Chairman & President and CEO Dan W Gladney .

Reshape Lifesciences Inc (RSLS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Reshape Lifesciences Inc (RSLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Reshape Lifesciences Inc (RSLS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Reshape Lifesciences Inc (RSLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Reshape Lifesciences Inc Insider Transactions

No Available Data

What does Altimmune Inc do?

Who are the key executives at Altimmune Inc?

Nicholas Galakatos is the other: See explanation below of Altimmune Inc. Other key executives at Altimmune Inc include Chief Financial Officer Richard I Eisenstadt , Chief Medical Officer Matthew Scott Harris , and Chief Business Officer Raymond M Jordt .

Altimmune Inc (ALT) Insider Trades Summary

Over the past 18 months, Nicholas Galakatos made no insider transaction in Altimmune Inc (ALT). Other recent insider transactions involving Altimmune Inc (ALT) include a net sale of 15,711 shares made by David Drutz ,

In summary, during the past 3 months, insiders sold 16,011 shares of Altimmune Inc (ALT) in total and bought 0 shares, with a net sale of 16,011 shares. During the past 18 months, 16,011 shares of Altimmune Inc (ALT) were sold and 300 shares were bought by its insiders, resulting in a net sale of 15,711 shares.

Altimmune Inc (ALT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Altimmune Inc Insider Transactions

No Available Data

What does ARYx Therapeutics Inc do?

Who are the key executives at ARYx Therapeutics Inc?

Nicholas Galakatos is the 10 percent owner of ARYx Therapeutics Inc. Other key executives at ARYx Therapeutics Inc include 10 percent owner Krishna Kittu Kolluri , 10 percent owner Growth Equity Opportunities Fund, Llc , and 10 percent owner Mark W Perry .

ARYx Therapeutics Inc (ARYX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ARYx Therapeutics Inc (ARYX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ARYx Therapeutics Inc (ARYX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ARYx Therapeutics Inc (ARYX)'s detailed insider trading history can be found in Insider Trading Tracker table.

ARYx Therapeutics Inc Insider Transactions

No Available Data

What does Metabasis Therapeutics Inc do?

Who are the key executives at Metabasis Therapeutics Inc?

Nicholas Galakatos is the 10 percent owner of Metabasis Therapeutics Inc. Other key executives at Metabasis Therapeutics Inc include 10 percent owner Ansbert Gadicke , 10 percent owner Michael Steinmetz , and 10 percent owner Mpm Asset Management Investors 2000b Llc .

Metabasis Therapeutics Inc (LGNZZ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Metabasis Therapeutics Inc (LGNZZ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Metabasis Therapeutics Inc (LGNZZ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Metabasis Therapeutics Inc (LGNZZ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Metabasis Therapeutics Inc Insider Transactions

No Available Data

What does Poniard Pharmaceuticals Inc do?

Who are the key executives at Poniard Pharmaceuticals Inc?

Nicholas Galakatos is the 10 percent owner of Poniard Pharmaceuticals Inc. Other key executives at Poniard Pharmaceuticals Inc include President & CMO Michael S Perry , director & Chief Executive Officer Ron Martell , and director & 10 percent owner Simon Nicholas J Iii .

Poniard Pharmaceuticals Inc (PARD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Poniard Pharmaceuticals Inc (PARD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Poniard Pharmaceuticals Inc (PARD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Poniard Pharmaceuticals Inc (PARD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Poniard Pharmaceuticals Inc Insider Transactions

No Available Data

What does Affymax Inc do?

Who are the key executives at Affymax Inc?

Nicholas Galakatos is the director & 10 percent owner of Affymax Inc. Other key executives at Affymax Inc include Chief Financial Officer Mark G Thompson , Chief Commercial Officer Jeffrey H Knapp , and Chief Financial Officer Herb Cross .

Affymax Inc (AFFY) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Affymax Inc (AFFY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Affymax Inc (AFFY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Affymax Inc (AFFY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Affymax Inc Insider Transactions

No Available Data

What does Rigel Pharmaceuticals Inc do?

Who are the key executives at Rigel Pharmaceuticals Inc?

Nicholas Galakatos is the 10 percent owner of Rigel Pharmaceuticals Inc. Other key executives at Rigel Pharmaceuticals Inc include Sr VP of Bus Dev and Com Ops Raul R Rodriguez , EVP & Chief Commercial Officer David A Santos , and EVP & Chief Financial Officer Dean L Schorno .

Rigel Pharmaceuticals Inc (RIGL) Insider Trades Summary

Over the past 18 months, Nicholas Galakatos made no insider transaction in Rigel Pharmaceuticals Inc (RIGL). Other recent insider transactions involving Rigel Pharmaceuticals Inc (RIGL) include a net sale of 52,894 shares made by Raul R Rodriguez , a net sale of 14,519 shares made by David A Santos , and a net sale of 12,628 shares made by Dean L Schorno .

In summary, during the past 3 months, insiders sold 0 shares of Rigel Pharmaceuticals Inc (RIGL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 8,004 shares of Rigel Pharmaceuticals Inc (RIGL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 8,004 shares.

Rigel Pharmaceuticals Inc (RIGL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rigel Pharmaceuticals Inc Insider Transactions

No Available Data

What does Cyclacel Pharmaceuticals Inc do?

Who are the key executives at Cyclacel Pharmaceuticals Inc?

Nicholas Galakatos is the 10 percent owner of Cyclacel Pharmaceuticals Inc. Other key executives at Cyclacel Pharmaceuticals Inc include director & President & C.E.O. Spiro Rombotis , director & E.V.P. & Finance & C.O.O. Paul Mcbarron , and Chief Medical Officer Mark Kirschbaum .

Cyclacel Pharmaceuticals Inc (CYCC) Insider Trades Summary

Over the past 18 months, Nicholas Galakatos made no insider transaction in Cyclacel Pharmaceuticals Inc (CYCC). Other recent insider transactions involving Cyclacel Pharmaceuticals Inc (CYCC) include a net purchase of 6,070 shares made by Spiro Rombotis , and a net purchase of 1,886 shares made by Paul Mcbarron .

In summary, during the past 3 months, insiders sold 0 shares of Cyclacel Pharmaceuticals Inc (CYCC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cyclacel Pharmaceuticals Inc (CYCC) were sold and 7,956 shares were bought by its insiders, resulting in a net purchase of 7,956 shares.

Cyclacel Pharmaceuticals Inc (CYCC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cyclacel Pharmaceuticals Inc Insider Transactions

No Available Data

What does Talaris Therapeutics Inc do?

Who are the key executives at Talaris Therapeutics Inc?

Nicholas Galakatos is the director of Talaris Therapeutics Inc. Other key executives at Talaris Therapeutics Inc include Interim CFO Ryan F. Robinson , Chief Medical Officer Yung H. Chyung , and CBO & GC and Secretary W Bradford Middlekauff .

Talaris Therapeutics Inc (TALS) Insider Trades Summary

Over the past 18 months, Nicholas Galakatos made no insider transaction in Talaris Therapeutics Inc (TALS). Other recent insider transactions involving Talaris Therapeutics Inc (TALS) include a net sale of 218,472 shares made by Suzanne Ildstad ,

In summary, during the past 3 months, insiders sold 0 shares of Talaris Therapeutics Inc (TALS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 21,847 shares of Talaris Therapeutics Inc (TALS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 21,847 shares.

Talaris Therapeutics Inc (TALS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Talaris Therapeutics Inc Insider Transactions

No Available Data

Nicholas Galakatos Mailing Address

Above is the net worth, insider trading, and ownership report for Nicholas Galakatos. You might contact Nicholas Galakatos via mailing address: The John Hancock Tower, 200 Clarendon Street, 54th Floor, Boston Ma 02116.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.